Pharmacist care in patients with heart failure significantly reduced the rate of all-cause hospitalizations (OR 0.71; 95% CI 0.54-0.94) and heart failure hospitalizations (OR 0.69; 95% CI 0.51-0.94).
Systematic Review (n=2,060)
Does pharmacist care reduce hospitalizations and mortality in patients with heart failure?
Pharmacist involvement in heart failure care teams significantly reduces the risk of all-cause and heart failure-specific hospitalizations.
Effect estimate: OR 0.71 (95% CI 0.54-0.94)
BACKGROUND: While the role of multidisciplinary teams in the treatment of patients with heart failure (HF) is well established, there is less evidence to characterize the role of individual team members. To clarify the role of pharmacists in the care of patients with HF, we performed a systematic review evaluating the effect of pharmacist care on patient outcomes in HF. METHODS: We searched PubMed, MEDLINE, EMBASE, International Pharmaceutical Abstracts, Web of Science, Scopus, Dissertation Abstracts, CINAHL, Pascal, and Cochrane Central Register of Controlled Trials for controlled studies from database inception to August 2007. We included randomized controlled trials that evaluated the impact of pharmacist care activities on patients with HF (in both inpatient and outpatient settings). Summary odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model for rates of all-cause hospitalization, HF hospitalization, and mortality. RESULTS: A total of 12 randomized controlled trials (2060 patients) were identified. Extent of pharmacist involvement varied among studies, and each study intervention was categorized as pharmacist-directed care or pharmacist collaborative care using a priori definitions and feedback from primary study authors. Pharmacist care was associated with significant reductions in the rate of all-cause hospitalizations (11 studies 2026 patients) (OR, 0.71; 95% CI, 0.54-0.94) and HF hospitalizations (11 studies 1977 patients) (OR, 0.69; 95% CI, 0.51-0.94),and a nonsignificant reduction in mortality (12 studies 2060 patients)(OR, 0.84; 95% CI, 0.61-1.15). Pharmacist collaborative care led to greater reductions in the rate of HF hospitalizations (OR, 0.42; 95%CI, 0.24-0.74) than pharmacist-directed care (OR, 0.89; 95% CI, 0.68-1.17). CONCLUSIONS: Pharmacist care in the treatment of patients with HF greatly reduces the risk of all-cause and HF hospitalizations. Since hospitalizations associated with HF are a major public health problem, the incorporation of pharmacists into HF care teams should be strongly considered.
Sheri L. Koshman (2008) conducted a systematic review in Heart failure (n=2,060). Pharmacist care vs. Control was evaluated on All-cause hospitalization (OR 0.71, 95% CI 0.54-0.94). Pharmacist care in patients with heart failure significantly reduced the rate of all-cause hospitalizations (OR 0.71; 95% CI 0.54-0.94) and heart failure hospitalizations (OR 0.69; 95% CI 0.51-0.94).